Mirabegron

Pronunciation: meer-a-BEG-ron.

Generic name
mirabegron
Drug class
Beta-3 adrenergic receptor agonist (urinary antispasmodic)
Form
Prolonged/extended-release tablet, 25 mg or 50 mg (also oral granules/suspension for some paediatric use)
Route
Oral
Legal status
Prescription-only

Availability and supply rules vary by country

Trade names by country: United States · United Kingdom · Canada · Australia · New Zealand

Australia: Betmiga (5) · Full directory

What mirabegron is and how it works

Mirabegron is a prescription-only medicine that helps relax the bladder muscle, used to treat overactive bladder symptoms such as urgency, frequent urination, and urge incontinence. (1)

Take mirabegron exactly as your prescriber directs. Your starting dose and whether it is later increased depend on your individual response, kidney and liver function, and blood pressure -- it is not a fixed dose for everyone.

Mechanism of action: how mirabegron works

Mirabegron is a selective beta-3 adrenoceptor agonist. Activating beta-3 receptors relaxes detrusor smooth muscle during the bladder's storage phase, increasing bladder capacity without impairing normal voiding contractions. (1) (2)

What mirabegron is used for

Overactive bladder (OAB)

Used in adults to treat overactive bladder symptoms, including urgency, increased urinary frequency, and urge urinary incontinence -- either alone or combined with another OAB medicine (solifenacin) in some countries. (1)

Neurogenic detrusor overactivity (children, some countries)

Used in some countries to treat neurogenic detrusor overactivity (a bladder-control problem linked to a nervous system condition) in children and adolescents aged 3 to under 18 years. (1) (2)

Before taking mirabegron

Do not take / not appropriate for

  • Do not take mirabegron if you have had a serious allergic reaction to it or any of its ingredients. (all countries) (1)
  • Do not take mirabegron if you have severe, uncontrolled high blood pressure (systolic 180 mmHg or higher, or diastolic 110 mmHg or higher). (all countries) (1) (2)

Tell your clinician about

  • Any history of high blood pressure, even if it is currently controlled.
  • Any difficulty emptying your bladder, an enlarged prostate, or other bladder outlet blockage.
  • If you take any other medicine for overactive bladder, especially an 'antimuscarinic' type.
  • Any kidney or liver problems.
  • If you take digoxin (a heart medicine), a beta-blocker such as metoprolol, or a tricyclic antidepressant.
  • Pregnancy, plans for pregnancy, or breastfeeding.
(1) (2)

How to take mirabegron

  • Take once daily, with or without food (adults); take with food if you are a child prescribed this medicine.
  • Swallow the tablet whole with liquid -- do not chew, divide, or crush it.
  • Keep your blood pressure check appointments while taking this medicine, especially if you have high blood pressure.
(1)

Procedures and treatment changes

Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1) (2) (3) (4) (5) (6)

Missed dose

If you miss a dose, take it as soon as you remember that day, then continue your normal schedule the next day. Do not take two doses to make up for a missed one. Contact your prescriber if you are unsure.

Overdose

Seek medical attention if you think too much has been taken, especially if you develop a fast heartbeat, palpitations, or a marked rise in blood pressure. (1)

Side effects

Side effects and their urgency vary; report severe, persistent, or concerning symptoms.

Raised blood pressure.

What to notice: Raised blood pressure.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1)

Common cold-like symptoms (nasopharyngitis).

What to notice: Common cold-like symptoms (nasopharyngitis).

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1)

Urinary tract infection.

What to notice: Urinary tract infection.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1)

Headache.

What to notice: Headache.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1)

Dry mouth, constipation, or a fast heartbeat (more often when combined with another OAB medicine).

What to notice: Dry mouth, constipation, or a fast heartbeat (more often when combined with another OAB medicine).

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1)

Serious warnings

Signs of a marked rise in blood pressure — high caution

Symptoms: Severe headache, visual disturbance, chest pain, or shortness of breath.

Action: Tell your prescriber promptly and seek urgent care for severe symptoms. Blood pressure is checked before starting and periodically during treatment, especially if you have existing hypertension. (1)

Signs of inability to empty the bladder (urinary retention) — high caution

Symptoms: Difficulty passing urine, a weak stream, or a feeling of incomplete emptying.

Action: Tell your prescriber promptly, especially if you have a known bladder outlet blockage or take another overactive-bladder medicine at the same time. (1)

Signs of angioedema (a serious swelling reaction) — emergency

Symptoms: Swelling of the face, lips, tongue, or throat, and/or difficulty breathing or swallowing.

Action: Seek emergency medical help immediately. This can occur after the first dose or later in treatment. (1)

Interactions

  • Digoxin (a heart medicine): mirabegron can raise digoxin blood levels -- your prescriber may start you on the lowest digoxin dose and monitor your digoxin blood levels. (1) (2)
  • Metoprolol and other beta-blockers, tricyclic antidepressants, and certain heart-rhythm medicines (such as flecainide or propafenone): mirabegron can raise their blood levels, so your prescriber may monitor you more closely or adjust doses. (1) (2)
  • Other overactive-bladder medicines that work by blocking muscarinic receptors can add to the risk of urinary retention when combined with mirabegron. (1)

Pregnancy, breastfeeding, kidney/liver function, age

Pregnancy

There is not enough human data on mirabegron in pregnancy. Some UK/EU guidance advises against use in pregnancy based on animal study findings -- discuss with your prescriber if you are pregnant or planning pregnancy. (1) (2) (3) (4) (5) (6)

Breastfeeding

Mirabegron passes into milk in animal studies and is expected to be present in human breast milk; UK/EU guidance advises against use while breastfeeding. Discuss feeding options with your prescriber. (1) (2) (3) (4) (5) (6)

Children

Approved in some countries for neurogenic detrusor overactivity from age 3, with dosing based on body weight. (1) (2) (3) (4) (5) (6)

Elderly

No specific dose adjustment based on age alone is described in the source reviewed, but blood pressure and kidney function are monitored regardless of age. (1) (2) (3) (4) (5) (6)

Hepatic_impairment

Dose may need to be limited or the medicine avoided in significant liver impairment -- tell your prescriber about any liver problems. (1) (2) (3) (4) (5) (6)

Renal_impairment

Dose may need to be reduced in significant kidney impairment, and the medicine is not recommended in end-stage kidney disease. (1) (2) (3) (4) (5) (6)

Monitoring

Before starting

  • Baseline blood pressure
  • Kidney and liver function
  • Review of other medicines, especially digoxin, beta-blockers, and other OAB medicines

During treatment

  • Periodic blood pressure checks, especially in people with existing hypertension.
  • Digoxin blood level monitoring if taken together.
  • Watching for symptoms of urinary retention, especially with bladder outlet blockage or antimuscarinic OAB medicines.
  • Watching for signs of angioedema.
(1)

Storage

Store tablets at controlled room temperature. If prescribed as granules for oral suspension, follow the specific mixing and in-use storage instructions provided with the product, including any time limit after reconstitution.

Professional information

Clinician-facing context only, sourced from the current US FDA prescribing information and UK SmPC; verify against the current full label before prescribing.

United States

Indication: Overactive bladder (adults); neurogenic detrusor overactivity (paediatric, 3 years and older)

Dose summary: Adults: 25mg once daily, may increase to 50mg once daily after 4-8 weeks. Paediatric NDO: weight-based (granules below 35kg; tablets from 35kg, starting 25mg, may increase to 50mg after 4-8 weeks). Reduce dose or avoid in severe renal/hepatic impairment; not recommended in ESRD or severe hepatic impairment.

Renal context: Severe renal impairment: dose typically limited to 25mg daily (per UK SmPC detail); not recommended in end-stage renal disease (eGFR under 15) or on haemodialysis. (1) (2)

Mechanism of action

Hepatic guidance

Dose reduction needed in moderate hepatic impairment; not recommended in severe hepatic impairment.

Overdose note

Overdose may cause a marked rise in heart rate, palpitations, or increased blood pressure; management is supportive, with monitoring of cardiovascular status. (1) (2)

Frequently asked questions

Is mirabegron available in the US, UK, Europe, Canada, Australia, and New Zealand?

Yes, it is approved in all of these regions, as Myrbetriq in the US and Canada and as Betmiga in the UK, Europe, Australia, and New Zealand. New Zealand availability is confirmed through a government medicines-funding review rather than a directly obtained Medsafe data sheet in this review. (1) (2) (3) (4) (5) (6)

Why does mirabegron need blood pressure monitoring?

Mirabegron can raise blood pressure, so it is not recommended for people with severe, uncontrolled high blood pressure, and your prescriber will check your blood pressure before starting and periodically during treatment. (1)

Can mirabegron cause a serious allergic reaction?

Yes, though it is uncommon. Mirabegron can cause angioedema -- swelling of the face, lips, tongue, or throat -- which can occur after the first dose or later in treatment and can be life-threatening if the airway is affected. Seek emergency care immediately for any swelling of the face or throat, or difficulty breathing or swallowing. (1)

What is the mechanism of action of mirabegron?

Mirabegron is a selective beta-3 adrenoceptor agonist. Activating beta-3 receptors relaxes detrusor smooth muscle during the bladder's storage phase, increasing bladder capacity without impairing normal voiding contractions. (1) (2)

What is the generic name of Mirabegron?

The generic name is mirabegron. (1)

What class of drug is mirabegron?

Mirabegron is classed as: Beta-3 adrenergic receptor agonist (urinary antispasmodic). (1)

References

  1. MYRBETRIQ (mirabegron extended-release tablets) and MYRBETRIQ GRANULES -- full prescribing information (initial US approval 2012)U.S. Food and Drug Administration / DailyMed (NIH), full prescribing information, Astellas Pharma US, Inc. · United States · accessed 2026-07-29 · source 1
  2. Mirabegron Astellas 50 mg prolonged-release tablets -- Summary of Product Characteristics (marketed in the UK as Betmiga)electronic medicines compendium (emc), United Kingdom -- Astellas Pharma Ltd · United Kingdom · accessed 2026-07-29 · source 2
  3. Betmiga European Public Assessment Report (EPAR)European Medicines Agency (EMA) · European Union · accessed 2026-07-29 · source 3
  4. MYRBETRIQ (mirabegron) Product MonographHealth Canada product monograph · Canada · accessed 2026-07-29 · source 4
  5. BETMIGA (mirabegron) 25mg and 50mg -- ARTG registrationsTherapeutic Goods Administration (TGA), Australia · Australia · accessed 2026-07-29 · source 5
  6. PTAC meeting record referencing mirabegron (Betmiga) funding review for overactive bladderPHARMAC (Pharmaceutical Management Agency) Pharmacology and Therapeutics Advisory Committee (PTAC), New Zealand · New Zealand · accessed 2026-07-29 · source 6

Brand names by country

Single-ingredient mirabegron names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.

Priority countries

United States

  • Myrbetriq25 mg, 8 mg/mL, 50 mg · astellas pharma us, inc.
  • Mirabgeorn50 mg · qilu pharmaceutical co., ltd.

United Kingdom

  • Betmiga (Mirabegron Astellas) (2)MHRA licensed emc smpc confirmed · 25 mg, 50 mg prolonged-release tablet · Astellas Pharma Ltd

Canada

  • MYRBETRIQ

Australia

  • Betmiga (5)TGA ARTG registered 2013-10-17 confirmed · 25 mg, 50 mg prolonged-release tablet · Astellas Pharma Australia Pty Ltd

New Zealand

  • Betmiga (6)PHARMAC funding review confirms marketed status medsafe datasheet not directly fetched · not specified in fetched source · Astellas
View brands in additional countries.

European Union

Betmiga (3)